DK3360878T3 - Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf - Google Patents

Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf Download PDF

Info

Publication number
DK3360878T3
DK3360878T3 DK16872413.6T DK16872413T DK3360878T3 DK 3360878 T3 DK3360878 T3 DK 3360878T3 DK 16872413 T DK16872413 T DK 16872413T DK 3360878 T3 DK3360878 T3 DK 3360878T3
Authority
DK
Denmark
Prior art keywords
manufacturing process
azetidine derivative
azetidine
derivative
manufacturing
Prior art date
Application number
DK16872413.6T
Other languages
Danish (da)
English (en)
Inventor
Yinong Xie
Zejin You
Zhiwen Deng
Jun Zhu
Ao Wang
Yan Feng
Dong Long
Hong Zeng
Hongmei Song
Qijun Ye
Wei Qi
Donghai Su
Lichun Wang
Jingyi Wang
Original Assignee
Sichuan Kelun Biotech Biopharmaceutica Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutica Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutica Co Ltd
Application granted granted Critical
Publication of DK3360878T3 publication Critical patent/DK3360878T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16872413.6T 2015-12-11 2016-12-08 Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf DK3360878T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510924946 2015-12-11
PCT/CN2016/109036 WO2017097224A1 (zh) 2015-12-11 2016-12-08 氮杂环丁烷衍生物、其制备方法及用途

Publications (1)

Publication Number Publication Date
DK3360878T3 true DK3360878T3 (da) 2020-11-09

Family

ID=59012693

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16872413.6T DK3360878T3 (da) 2015-12-11 2016-12-08 Azetidinderivat, fremstillingsfremgangsmåde derfor og anvendelse deraf

Country Status (8)

Country Link
US (3) US10159662B2 (enExample)
EP (1) EP3360878B9 (enExample)
JP (1) JP6860267B2 (enExample)
CN (1) CN108137603B (enExample)
DK (1) DK3360878T3 (enExample)
ES (1) ES2830446T3 (enExample)
HK (1) HK1250707B (enExample)
WO (1) WO2017097224A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10159662B2 (en) * 2015-12-11 2018-12-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
EP3572415B1 (en) * 2017-01-23 2024-03-06 Shanghai Longwood Biopharmaceuticals Co., Ltd. Jak kinase inhibitor and preparation method and use thereof
ES2937823T3 (es) 2017-06-07 2023-03-31 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Forma sólida del derivado de azetidina y método de preparación del mismo y uso del mismo
BR112020008850A2 (pt) * 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CN109867675B (zh) * 2017-12-01 2021-01-19 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
TW201940483A (zh) * 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
JP7591500B2 (ja) 2018-08-10 2024-11-28 アクラリス セラピューティクス,インコーポレイテッド ピロロピリミジンitk阻害剤
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN111518096B (zh) * 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
WO2020173364A1 (zh) * 2019-02-27 2020-09-03 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PL3954689T3 (pl) 2019-04-12 2024-08-05 Primegene (Beijing) Co., Ltd. Związki pochodne pirazolopirazyny, kompozycja farmaceutyczna i ich zastosowanie
PH12021552036A1 (en) 2019-05-02 2022-05-23 Aclaris Therapeutics Inc Substituted pyrrolopyridines as jak inhibitors
CN110028432A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种(3-氨基-氮杂环丁烷-1-基)-环丙基-甲酮的制备方法
EP3976612A4 (en) * 2019-05-28 2023-04-26 Mankind Pharma Ltd NEW COMPOUNDS FOR INHIBITION OF JANUS KINASE 1
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN118786125A (zh) * 2022-03-18 2024-10-15 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物的用途及治疗方法
WO2023226822A1 (zh) * 2022-05-26 2023-11-30 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物治疗病毒感染的方法及用途
CN115974864B (zh) * 2022-12-29 2025-09-16 苏州汉德创宏生化科技有限公司 一种2-(3-氮杂环丁基)噻唑盐的合成方法
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
WO2024153147A1 (zh) * 2023-01-18 2024-07-25 北京普祺医药科技股份有限公司 一种氮杂环烷烃化合物、药物组合物及其用途
CN116444529B (zh) * 2023-06-16 2023-12-05 药康众拓(江苏)医药科技有限公司 一种氘代氮杂环丁烷类jak抑制剂及其用途
WO2025264695A1 (en) * 2024-06-20 2025-12-26 Elanco Us Inc. Compositions and methods for treatment
WO2026092417A1 (zh) * 2024-10-28 2026-05-07 四川青木制药有限公司 Jak抑制剂的中间体、晶型及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
MY165582A (en) * 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US8691807B2 (en) * 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CA3158254C (en) 2014-04-08 2024-05-21 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
SG10201912302VA (en) 2015-02-27 2020-02-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
US10159662B2 (en) * 2015-12-11 2018-12-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
EP3360878B1 (en) 2020-09-16
HK1250707B (zh) 2020-07-03
CN108137603B (zh) 2019-10-18
JP6860267B2 (ja) 2021-04-14
US10159662B2 (en) 2018-12-25
JP2018536634A (ja) 2018-12-13
EP3360878B9 (en) 2021-05-05
WO2017097224A1 (zh) 2017-06-15
EP3360878A4 (en) 2019-03-06
US20180289680A1 (en) 2018-10-11
US20200147062A1 (en) 2020-05-14
ES2830446T3 (es) 2021-06-03
US11045455B2 (en) 2021-06-29
HK1251551A1 (en) 2019-02-01
EP3360878A1 (en) 2018-08-15
US20190060291A1 (en) 2019-02-28
CN108137603A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
FIC20240040I1 (fi) Krovalimabi
DK3168283T3 (da) Hydrokrakning-katalysator, fremstillingsfremgangsmåde og anvendelse deraf
DK3134149T3 (da) Mikrokanyler og fremgangsmåder til fremstilling deraf
PL3345230T3 (pl) Podwójny perowskit
HRP20181692T1 (hr) Liječenje fibroze
DK4036094T3 (da) Erstattede 4-fenylpiperidiner, deres fremstilling og anvendelse
DK3151985T3 (da) Bukkemaskine og tilsvarende fremgangsmåde
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3050848T3 (da) Molekylesi, fremstillingsfremgangsmåde og anvendelse deraf
PT3139979T (pt) Unidade, nebulizador e método
DK3161124T3 (da) Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3341479T3 (da) LNA-G-Proces
DK3265123T3 (da) Antistoffer, anvendelser og fremgangsmåder
HUE057118T2 (hu) Folyamat
PT3412648T (pt) Método de fabrico de 1,1,3,3-tetracloropropeno
DK3125243T3 (da) Lydafkodningsindretning, lydkodningsindretning, lydafkodningsfremgangsmåde, lydkodningsfremgangsmåde, lydafkodningsprogram og lydkodningsprogram
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3284797T3 (da) Sammensætning, der omfatter hfc og hfo
IL259234B (en) Cephem compounds, their production and use
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3380496T3 (da) Forbedret proteinproduktion og fremgangsmåder hertil